XNK Therapeutics has announced the appointment of Markus Thor as Chief Business Officer.
Thor will be member of the company’s management team.
“Markus is a welcome addition to the XNK team,” says Johan Liwing, CEO of XNK Therapeutics. “Markus has an extensive business development background which will be incredibly useful to XNK as the company continues to scale.”
Thor is an experienced business development executive with 25 years’ experience from the life science industry. In previous roles he was responsible for structuring, negotiating and closing a range of global, strategic business agreements, including in- and out-licensing, acquisitions and R&D collaborations.
Prior to joining XNK, Thor worked more than a decade at Biovitrum AB, iNovacia AB and Kancera AB leading business development. He joins most recently from consulting and supporting life science companies with their business development efforts since 2013. Thor received his MBA from Stockholm School of Economics and his MSc in Chemistry from the University of Umeå in Sweden and the University of Sussex, UK.
“XNK has a unique approach to immunotherapy, and I am thrilled by the idea of helping the company reach its ambitions,” says Markus Thor. “I look forward to joining the team during such an exciting time.”